|1.||Soni, Madhu G: 1 article (07/2013)|
|2.||Moran, Daniel L: 1 article (07/2013)|
|3.||Marone, Palma Ann: 1 article (07/2013)|
|4.||Bauter, Mark R: 1 article (07/2013)|
|5.||Goh, Tatsuaki: 1 article (05/2004)|
|6.||Kuchitsu, Kazuyuki: 1 article (05/2004)|
|7.||Furuichi, Takuya: 1 article (05/2004)|
|8.||Higashi, Katsumi: 1 article (05/2004)|
|9.||Ogasawara, Yoko: 1 article (05/2004)|
|10.||Muto, Shoshi: 1 article (05/2004)|
|1.||Body Weight (Weight, Body)
07/01/2013 - "For this study, Sprague-Dawley (Hsd:SD) rats (10/sex/group) were administered via oral gavage 0 (control), 92.6, 462.9, and 926.0mg/kg body weight (bw)/day of Apoaequorin preparation, for 90 days. "
07/01/2013 - "There were no clinical or ophthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology or histopathological changes attributable to administration of Apoaequorin. "
05/07/2004 - "Cosuppression of NtTPC1s in apoaequorin-expressing BY-2 cells resulted in inhibition of rise in cytosolic free Ca(2+) concentration ([Ca(2+)](cyt)) in response to sucrose and a fungal elicitor cryptogein, while it did not affect hypoosmotic shock-induced [Ca(2+)](cyt) increase. "
05/01/1996 - "The moss, Physcomitrella patens, transformed with apoaequorin cDNA responds to cold shock, mechanical perturbation and pH with transient increases in cytoplasmic calcium."
|1.||Complementary DNA (cDNA)
|4.||algal cryptogein protein